Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Dose Escalation, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-hodgkin's Lymphoma

NCT04089527 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04089527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04089527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Dose Escalation, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-hodgkin's Lymphoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2019
Completion date
October 25, 2021
Enrollment
24 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin